# Compliance to the Treatment With GRAZAX® Tablets in Patients With Seasonal Grass Pollen Rhinoconjunctivitis

> **NCT01728285** · PHASE3 · COMPLETED · sponsor: **ALK-Abelló A/S** · enrollment: 261 (actual)

## Conditions studied

- Allergic Rhinitis
- Grass Allergy

## Interventions

- **DEVICE:** Electronic compliance device (Memozax®)

## Key facts

- **NCT ID:** NCT01728285
- **Lead sponsor:** ALK-Abelló A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2009-06
- **Final completion:** 2009-10
- **Target enrollment:** 261 (ACTUAL)
- **Last updated:** 2012-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01728285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01728285, "Compliance to the Treatment With GRAZAX® Tablets in Patients With Seasonal Grass Pollen Rhinoconjunctivitis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01728285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*